Triple threat: new combo therapy targets advanced lung cancer
NCT ID NCT03965468
First seen Feb 20, 2026 · Last updated Jun 11, 2026 · Updated 18 times
Summary
This study tests a new approach for people with stage IV non-small cell lung cancer that has spread to only a few other places (oligometastatic). Participants receive immunotherapy and chemotherapy, plus precise radiation to the metastases, followed by surgery or radiation to the main lung tumor. The goal is to see if this combination can delay cancer growth or improve survival. 96 adults are enrolled in this phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, Switzerland
-
Erasmus Medical Centre
Rotterdam, Netherlands
-
European Institute of Oncology
Milan, Italy
-
Geneva University Hospital
Geneva, Switzerland
-
Hosp. De la Santa Creu i Sant Pau
Barcelona, Spain
-
Hosp. Sanchinarro- Centro Integral Oncología Clara Campal
Madrid, Spain
-
Hosp. Uni. Politécnico La Fe
Valencia, Spain
-
Hosp. Uni. Virgen de las Nieves
Granada, Spain
-
IRCCS Istituto Nazionale Tumori Regina Elena
Roma, Italy
-
Inselspital Bern
Bern, Switzerland
-
Istituto Oncologico Veneto - Irccs
Padova, Italy
-
Kantonsspital Winterthur
Winterthur, Switzerland
-
Maastricht University Medical Center
Maastricht, Netherlands
-
University Hospital Zurich
Zurich, Switzerland
-
Vall d'Hebron University Hospital
Madrid, Spain
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.